Zanfel Laboratories, Inc. – Trademark Portfolio
Entity Type: 03
Zanfel Laboratories, Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 41 (Education & Entertainment) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include ZANFEL and 30 SECONDS. The owner is based in Woodstock, IL.
1105 Moraine Drive
Woodstock, IL 60098
Showing of trademarks Trademarks
Trademark Classifications
Zanfel Laboratories, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Education; providing of training; entertainment; sporting and cultural activities
Insurance; financial affairs; monetary affairs; real estate affairs
Frequently Asked Questions
How many trademarks does Zanfel Laboratories, Inc. have?
Zanfel Laboratories, Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 cancelled.
What trademark classes does Zanfel Laboratories, Inc. file in?
Zanfel Laboratories, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 36 (Insurance & Financial). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Zanfel Laboratories, Inc.'s most well-known trademarks?
Zanfel Laboratories, Inc.'s registered trademark portfolio includes well-known marks such as ZANFEL and 30 SECONDS. These are among 3 currently registered trademarks in the portfolio.
What is Zanfel Laboratories, Inc.'s trademark registration success rate?
Zanfel Laboratories, Inc. has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.